NCT05396235View on ClinicalTrials.gov

A Clinical Pharmacology Study of MT-3921 in Healthy Adult Males

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 3, 2022

Primary Completion Date

December 24, 2022

Study Completion Date

December 24, 2022

Conditions
Healthy Adult Males
Interventions
BIOLOGICAL

MT-3921

Solution for infusion; Intravenous (IV)

BIOLOGICAL

Placebo

Solution for infusion; Intravenous (IV)

Trial Locations (1)

162-0053

Clinical Research Hospital Tokyo, Shinjuku-ku

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY